
SPTX Stock Forecast & Price Target
SPTX Analyst Ratings
Bulls say
Seaport Therapeutics is a promising clinical-stage therapeutics company with a strong management team and valuable assets in the Glyph2BLSD program. Their focus on validated mechanisms and innovative drug delivery technology gives them a competitive edge in the market, but as a young company, there are risks and uncertainties to consider. The ongoing clinical trials for their lead assets, GlyphAllo and GlyphAgo, will be crucial in determining the success and future growth of the company.
Bears say
Seaport Therapeutics is a clinical-stage therapeutics company focused on developing new medicines for patients with depression and anxiety, but its stock faces risks due to potential competition and litigation around its patented lymphatic-targeting prodrug technology, Glyph. While the company has shown promising results in initial studies with its lead assets, GlyphAllo and GlyphAgo, there are risks associated with the limited operating history of the company and the highly litigious nature of the pharmaceutical industry. Additionally, the brexanolone and zuranolone compounds, which work on a similar receptor as Glyph, were not successful in clinical trials and may suggest potential issues for Seaport's compounds as well. However, Seaport's CEO Daphne Zohar has a successful track record in the industry, and the company is conducting ongoing efforts to safeguard and strengthen its patent position.
This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SPTX Analyst Forecast & Price Prediction
Start investing in SPTX
Order type
Buy in
Order amount
Est. shares
0 shares